Evaluation of CLP in Heart Failure Patients With Chronic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 113 participants.

Also called NCT01265524

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 113 participants (enrolled count) (from the registry)
Sponsor
Sorbent Therapeutics (from the registry)
Registry
  • NCT NCT01265524
Main results
  • A double-blind, randomized, parallel, placebo-controlled study examining the effect of cross-linked polyelectrolyte in heart failure patients with chronic kidney disease European journal of heart failure, 2012-08 DOI, PubMed 22613585

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
Not reported
Results first posted
(from the registry)
Countries
Armenia, Georgia, Moldova (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01265524. Randomized; quadruple masking; primary purpose prevention. Start 2011-04 (registry gives no type); primary completion 2011-11 (actual). Results posted on 2013-03-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of CLP in Heart Failure Patients With Chronic Kidney Disease
Condition
Heart Failure
Intervention (Drug)
CLP
Intervention (Drug)
Placebo
Lead sponsor
Sorbent Therapeutics (class: industry)
Collaborator
Pharmaterra (class: not stated)

Record details

Record id
cardio:ct-nct01265524
Content hash
c8a8bd16b3b7a2bb9247423b13478c716aef336ab41097ea03ba981a43d8563b